SYNformulas GmbH

SYNformulas GmbH is a global leader in the probiotics industry, focusing on researching intelligent bacteria for the therapy of patients with allergies and gastrointestinal diseases. Under the brand name Kijimea®, the company develops and distributes medical products, dietary supplements, and products for supplementary balanced diets. The company achieved a breakthrough in the treatment of irritable bowel diseases, with the patented bacteria strain MIMBb75 showing significant efficacy in two independent studies for irritable bowel syndrome. Recently, it was included in the updated S3 guideline for irritable bowel syndrome, the standard guideline for clinical practice. The company, founded in 2011 and headquartered in Germany, is focused on pioneering product development with clinically proven efficacy, relying on a knowledgeable research and development team, as well as collaboration with a wide network of internationally recognized researchers and universities. The company has not disclosed its last investment or the investors involved. SYNformulas GmbH operates within the Biopharma, Health Care, and Pharmaceutical industries.